2. Amyotrophic lateral sclerosis Clinical trials / Disease details
Clinical trials : 645 / Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04745299 (ClinicalTrials.gov) | March 23, 2021 | 27/1/2021 | Evaluation the Efficacy and Safety of Mutiple Lenzumestrocel (Neuronata-R® Inj.) Treatment in Patients With ALS | A Double-blind, Randomized, Multicenter, Placebo-Controlled, Parallel, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Lenzumestrocel(Neuronata-R® Inj.) in Patients With Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Biological: Lenzumestrocel;Drug: Riluzole;Drug: Placebo Comparator | Corestem, Inc. | NULL | Recruiting | 25 Years | 75 Years | All | 115 | Phase 3 | Korea, Republic of |